Latest & greatest articles for azithromycin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on azithromycin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on azithromycin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for azithromycin

1. Azithromycin for Early Pseudomonas Infection in Cystic Fibrosis. The OPTIMIZE Randomized Trial

Azithromycin for Early Pseudomonas Infection in Cystic Fibrosis. The OPTIMIZE Randomized Trial 29890086 2018 11 15 1535-4970 198 9 2018 Nov 01 American journal of respiratory and critical care medicine Am. J. Respir. Crit. Care Med. Azithromycin for Early Pseudomonas Infection in Cystic Fibrosis. The OPTIMIZE Randomized Trial. 1177-1187 10.1164/rccm.201802-0215OC New isolation of Pseudomonas aeruginosa (Pa) is generally treated with inhaled antipseudomonal antibiotics such as tobramycin (...) inhalation solution (TIS). A therapeutic approach that complements traditional antimicrobial therapy by reducing the risk of pulmonary exacerbation and inflammation may ultimately prolong the time to Pa recurrence. To test the hypothesis that the addition of azithromycin to TIS in children with cystic fibrosis and early Pa decreases the risk of pulmonary exacerbation and prolongs the time to Pa recurrence. The OPTIMIZE (Optimizing Treatment for Early Pseudomonas aeruginosa Infection in Cystic Fibrosis

EvidenceUpdates2018

2. Amoxicillin-clavulanate versus azithromycin for respiratory exacerbations in children with bronchiectasis (BEST-2): a multicentre, double-blind, non-inferiority, randomised controlled trial.

Amoxicillin-clavulanate versus azithromycin for respiratory exacerbations in children with bronchiectasis (BEST-2): a multicentre, double-blind, non-inferiority, randomised controlled trial. BACKGROUND: Although amoxicillin-clavulanate is the recommended first-line empirical oral antibiotic treatment for non-severe exacerbations in children with bronchiectasis, azithromycin is also often prescribed for its convenient once-daily dosing. No randomised controlled trials involving acute (...) exacerbations in children with bronchiectasis have been published to our knowledge. We hypothesised that azithromycin is non-inferior to amoxicillin-clavulanate for resolving exacerbations in children with bronchiectasis. METHODS: We did this parallel-group, double-dummy, double-blind, non-inferiority randomised controlled trial in three Australian and one New Zealand hospital between April, 2012, and August, 2016. We enrolled children aged 1-19 years with radiographically proven bronchiectasis unrelated

Lancet2018

3. Azithromycin

Azithromycin Top results for azithromycin - Trip Database or use your Google+ account Turning Research Into Practice My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box (...) and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for azithromycin The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical

Trip Latest and Greatest2018

4. Azithromycin to Reduce Childhood Mortality in Sub-Saharan Africa.

Azithromycin to Reduce Childhood Mortality in Sub-Saharan Africa. BACKGROUND: We hypothesized that mass distribution of a broad-spectrum antibiotic agent to preschool children would reduce mortality in areas of sub-Saharan Africa that are currently far from meeting the Sustainable Development Goals of the United Nations. METHODS: In this cluster-randomized trial, we assigned communities in Malawi, Niger, and Tanzania to four twice-yearly mass distributions of either oral azithromycin (...) monitored. The mean (±SD) azithromycin and placebo coverage over the four twice-yearly distributions was 90.4±10.4%. The overall annual mortality rate was 14.6 deaths per 1000 person-years in communities that received azithromycin (9.1 in Malawi, 22.5 in Niger, and 5.4 in Tanzania) and 16.5 deaths per 1000 person-years in communities that received placebo (9.6 in Malawi, 27.5 in Niger, and 5.5 in Tanzania). Mortality was 13.5% lower overall (95% confidence interval [CI], 6.7 to 19.8) in communities

NEJM2018

5. Azithromycin and metronidazole versus metronidazole-based therapy for the induction of remission in mild to moderate paediatric Crohn`s disease : a randomised controlled trial

Azithromycin and metronidazole versus metronidazole-based therapy for the induction of remission in mild to moderate paediatric Crohn`s disease : a randomised controlled trial 29420227 2018 02 08 1468-3288 2018 Feb 02 Gut Gut Azithromycin and metronidazole versus metronidazole-based therapy for the induction of remission in mild to moderate paediatric Crohn's disease : a randomised controlled trial. gutjnl-2017-315199 10.1136/gutjnl-2017-315199 Crohn's disease (CD) pathogenesis associated (...) with dysbiosis and presence of pathobionts in the lumen, intracellular compartments and epithelial biofilms. Azithromycin is active in all three compartments. Our goal was to evaluate if azithromycin-based therapy can improve response and induce remission compared with metronidazole alone in paediatric CD. This blinded randomised controlled trial allocated children 5-18 years with 10azithromycin 7.5 mg/kg, 5 days/week for 4 weeks and 3 days/week

EvidenceUpdates2018

6. Re-emergence of yaws after single mass azithromycin treatment followed by targeted treatment: a longitudinal study.

Re-emergence of yaws after single mass azithromycin treatment followed by targeted treatment: a longitudinal study. BACKGROUND: Yaws is a substantial cause of chronic disfiguring ulcers in children in at least 14 countries in the tropics. WHO's newly adopted strategy for yaws eradication uses a single round of mass azithromycin treatment followed by targeted treatment programmes, and data from pilot studies have shown a short-term significant reduction of yaws. We assessed the long-term (...) for Treponema pallidum was the primary outcome indicator. The study is registered with ClinicalTrials.gov, number NCT01955252 . FINDINGS: Mass azithromycin treatment (coverage rate of 84%) followed by targeted treatment programmes reduced the prevalence of active yaws from 1·8% to a minimum of 0·1% at 18 months (difference from baseline -1·7%, 95% CI, -1·9 to -1·4; p<0·0001), but the infection began to re-emerge after 24 months with a significant increase to 0·4% at 42 months (difference from 18 months 0

Lancet2018

7. Effect of Azithromycin on Airflow Decline-Free Survival After Allogeneic Hematopoietic Stem Cell Transplant: The ALLOZITHRO Randomized Clinical Trial.

Effect of Azithromycin on Airflow Decline-Free Survival After Allogeneic Hematopoietic Stem Cell Transplant: The ALLOZITHRO Randomized Clinical Trial. Importance: Bronchiolitis obliterans syndrome has been associated with increased morbidity and mortality after allogeneic hematopoietic stem cell transplant (HSCT). Previous studies have suggested that azithromycin may reduce the incidence of post-lung transplant bronchiolitis obliterans syndrome. Objective: To evaluate if the early (...) administration of azithromycin can improve airflow decline-free survival after allogeneic HSCT. Design, Setting, and Participants: The ALLOZITHRO parallel-group trial conducted in 19 French academic transplant centers and involving participants who were at least 16 years old, had undergone allogeneic HSCT for a hematological malignancy, and had available pretransplant pulmonary function test results. Enrollment was from February 2014 to August 2015 with follow-up through April 26, 2017. Interventions

JAMA2017

8. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial.

Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. BACKGROUND: Exacerbations of asthma cause a substantial global illness burden. Adults with uncontrolled persistent asthma despite maintenance treatment require additional therapy. Since macrolide antibiotics can be used to treat persistent asthma, we aimed to assess the efficacy and safety of oral azithromycin as add (...) -on therapy in patients with uncontrolled persistent asthma on medium-to-high dose inhaled corticosteroids plus a long-acting bronchodilator. METHODS: We did a randomised, double-blind, placebo controlled parallel group trial to determine whether oral azithromycin decreases the frequency of asthma exacerbations in adults (≥18 years) with symptomatic asthma despite current use of inhaled corticosteroid and long-acting bronchodilator, and who had no hearing impairment or abnormal prolongation

Lancet2017

9. Use of azithromycin and risk of ventricular arrhythmia

Use of azithromycin and risk of ventricular arrhythmia 28420680 2017 04 19 2017 04 21 2017 04 23 1488-2329 189 15 2017 Apr 18 CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne CMAJ Use of azithromycin and risk of ventricular arrhythmia. E560-E568 10.1503/cmaj.160355 There are conflicting findings from observational studies of the arrhythrogenic potential of azithromycin. Our aim was to quantify the association between azithromycin use and the risk (...) of ventricular arrhythmia. We conducted a nested case-control study within a cohort of new antibiotic users identified from a network of 7 population-based health care databases in Denmark, Germany, Italy, the Netherlands and the United Kingdom for the period 1997-2010. Up to 100 controls per case were selected and matched by age, sex and database. Recency of antibiotic use and type of drug (azithromycin was the exposure of interest) at the index date (occurrence of ventricular arrhythmia) were identified

EvidenceUpdates2017 Full Text: Link to full Text with Trip Pro

10. The Adjunct Use of Azithromycin with Nonsurgical Periodontal Therapy Produces Probing Depth Reductions Similar to Metronidazole-Amoxicillin in Patients with Generalized Aggressive Periodontitis

The Adjunct Use of Azithromycin with Nonsurgical Periodontal Therapy Produces Probing Depth Reductions Similar to Metronidazole-Amoxicillin in Patients with Generalized Aggressive Periodontitis UTCAT3118, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title The Adjunct Use of Azithromycin with Nonsurgical Periodontal Therapy Produces Probing Depth Reductions Similar to Metronidazole-Amoxicillin in Patients with Generalized (...) Aggressive Periodontitis Clinical Question For patients with generalized aggressive periodontitis treated with nonsurgical periodontal therapy, will the use of adjunct systemic azithromycin compared to the use of metronidazole-amoxicillin in combination result in greater probing depth reduction? Clinical Bottom Line For patients with generalized aggressive periodontitis, nonsurgical periodontal therapy treatment in conjunction with systemic azithromycin produced similar probing depth reduction

UTHSCSA Dental School CAT Library2016

11. Adjunct Use of Systemic Azithromycin with Scaling and Root Planing in Treatment of Chronic Periodontitis Results in Only Limited Gain in Clinical Attachment Level and Limited Probing Depth Reduction

Adjunct Use of Systemic Azithromycin with Scaling and Root Planing in Treatment of Chronic Periodontitis Results in Only Limited Gain in Clinical Attachment Level and Limited Probing Depth Reduction UTCAT3102, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Adjunct Use of Systemic Azithromycin with Scaling and Root Planing in Treatment of Chronic Periodontitis Results in Only Limited Gain in Clinical Attachment Level (...) and Limited Probing Depth Reduction Clinical Question In a patient with chronic periodontitis, how does adjunct systemic azithromycin in conjunction with scaling and root planing versus scaling and root planing alone compare in terms of periodontal outcomes including probing depths and clinical attachment levels? Clinical Bottom Line Systemic use of azithromycin in chronic periodontitis patients has only limited benefits in terms of clinical attachment level gains and probing depth reduction based

UTHSCSA Dental School CAT Library2016

12. A randomised, double-blind, placebo-controlled study to evaluate the efficacy of oral azithromycin as a supplement to standard care for adult patients with acute exacerbations of asthma (the AZALEA trial)

A randomised, double-blind, placebo-controlled study to evaluate the efficacy of oral azithromycin as a supplement to standard care for adult patients with acute exacerbations of asthma (the AZALEA trial) A randomised, double-blind, placebo-controlled study to evaluate the efficacy of oral azithromycin as a supplement to standard care for adult patients with acute exacerbations of asthma (the AZALEA trial) Journals Library An error occurred retrieving content to display, please try again (...) . >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> {{metadata.Title}} {{metadata.Headline}} In adults with acute exacerbations of asthma, giving azithromycin in addition to standard care produced no statistically significant or clinically important benefit. {{author}} {{($index

NIHR HTA programme2016

13. Adjunctive Azithromycin Prophylaxis for Cesarean Delivery.

Adjunctive Azithromycin Prophylaxis for Cesarean Delivery. BACKGROUND: The addition of azithromycin to standard regimens for antibiotic prophylaxis before cesarean delivery may further reduce the rate of postoperative infection. We evaluated the benefits and safety of azithromycin-based extended-spectrum prophylaxis in women undergoing nonelective cesarean section. METHODS: In this trial conducted at 14 centers in the United States, we studied 2013 women who had a singleton pregnancy (...) with a gestation of 24 weeks or more and who were undergoing cesarean delivery during labor or after membrane rupture. We randomly assigned 1019 to receive 500 mg of intravenous azithromycin and 994 to receive placebo. All the women were also scheduled to receive standard antibiotic prophylaxis. The primary outcome was a composite of endometritis, wound infection, or other infection occurring within 6 weeks. RESULTS: The primary outcome occurred in 62 women (6.1%) who received azithromycin and in 119 (12.0

NEJM2016

14. Azithromycin versus Doxycycline for Chlamydia.

Azithromycin versus Doxycycline for Chlamydia. Azithromycin versus Doxycycline for Chlamydia. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 27144856 Format MeSH and Other Data E-mail Subject Additional text E (...) -mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2016 May 5;374(18):1787. doi: 10.1056/NEJMc1600830. Azithromycin versus Doxycycline for Chlamydia. , , . Comment on [N Engl J Med. 2015] [N Engl J Med. 2016] [N Engl J Med. 2016] PMID: 27144856 DOI: [Indexed for MEDLINE] Free full text Publication types MeSH terms Substances Full Text Sources Medical Miscellaneous PubMed Commons 0 comments

NEJM2016

15. Azithromycin versus Doxycycline for Chlamydia.

Azithromycin versus Doxycycline for Chlamydia. Azithromycin versus Doxycycline for Chlamydia. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 27144857 Format MeSH and Other Data E-mail Subject Additional text E (...) -mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2016 May 5;374(18):1786. doi: 10.1056/NEJMc1600830#SA1. Azithromycin versus Doxycycline for Chlamydia. 1 . 1 University of California, San Francisco, San Francisco, CA julius.schachter@ucsf.edu. Comment in [N Engl J Med. 2016] Comment on [N Engl J Med. 2015] PMID: 27144857 DOI: [Indexed for MEDLINE] Publication types MeSH terms Substances

NEJM2016 Full Text: Link to full Text with Trip Pro

16. Azithromycin versus Doxycycline for Chlamydia.

Azithromycin versus Doxycycline for Chlamydia. Azithromycin versus Doxycycline for Chlamydia. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 27144858 Format MeSH and Other Data E-mail Subject Additional text E (...) -mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2016 May 5;374(18):1786-7. doi: 10.1056/NEJMc1600830#SA2. Azithromycin versus Doxycycline for Chlamydia. 1 , 2 . 1 Helios St. Elisabeth Hospital, Oberhausen, Germany alexander.kreuter@helios-kliniken.de. 2 University of Cologne, Cologne, Germany. Comment in [N Engl J Med. 2016] Comment on [N Engl J Med. 2015] PMID: 27144858 DOI: [Indexed

NEJM2016 Full Text: Link to full Text with Trip Pro

17. Azithromycin for Recurrent Respiratory Tract Infections in Pediatric Populations

Azithromycin for Recurrent Respiratory Tract Infections in Pediatric Populations "Azithromycin for Recurrent Respiratory Tract Infections in Pediatric P" by Mikala Guadalupe Pino < > > > > > Title Author Date of Award Summer 8-13-2016 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies Rights . Abstract Background: Severe lower respiratory tract infections in pediatric populations result in millions of hospitalizations worldwide. Some children experience (...) recurrent symptoms and progressive episodes multiple times a year. Azithromycin has demonstrated not only antimicrobial but also potential antiviral and anti-inflammatory properties. Can azithromycin decrease disease severity or recurrence in pediatric patients with debilitating chronic respiratory tract symptoms? Methods: Exhaustive search of available medical literature was performed using MEDLINE-Ovid, Web of Science, and CINAHL. The search terms azithromycin, respiratory tract infection, lower

Pacific University EBM Capstone Project2016

18. Early Administration of Azithromycin and Prevention of Severe Lower Respiratory Tract Illnesses in Preschool Children With a History of Such Illnesses: A Randomized Clinical Trial.

Early Administration of Azithromycin and Prevention of Severe Lower Respiratory Tract Illnesses in Preschool Children With a History of Such Illnesses: A Randomized Clinical Trial. 26575060 2015 11 20 2015 12 24 2017 01 23 1538-3598 314 19 2015 Nov 17 JAMA JAMA Early Administration of Azithromycin and Prevention of Severe Lower Respiratory Tract Illnesses in Preschool Children With a History of Such Illnesses: A Randomized Clinical Trial. 2034-44 10.1001/jama.2015.13896 Many preschool children (...) develop recurrent, severe episodes of lower respiratory tract illness (LRTI). Although viral infections are often present, bacteria may also contribute to illness pathogenesis. Strategies that effectively attenuate such episodes are needed. To evaluate if early administration of azithromycin, started prior to the onset of severe LRTI symptoms, in preschool children with recurrent severe LRTIs can prevent the progression of these episodes. A randomized, double-blind, placebo-controlled, parallel-group

JAMA2015

19. Azithromycin in early infancy and pyloric stenosis

Azithromycin in early infancy and pyloric stenosis 25687145 2015 03 03 2015 04 28 2017 01 13 1098-4275 135 3 2015 Mar Pediatrics Pediatrics Azithromycin in early infancy and pyloric stenosis. 483-8 10.1542/peds.2014-2026 Use of oral erythromycin in infants is associated with infantile hypertrophic pyloric stenosis (IHPS). The risk with azithromycin remains unknown. We evaluated the association between exposure to oral azithromycin and erythromycin and subsequent development of IHPS (...) . A retrospective cohort study of children born between 2001 and 2012 was performed utilizing the military health system database. Infants prescribed either oral erythromycin or azithromycin as outpatients in the first 90 days of life were evaluated for development of IHPS. Specific diagnostic and procedural codes were used to identify cases of IHPS. A total of 2466 of 1 074 236 children in the study period developed IHPS. Azithromycin exposure in the first 14 days of life demonstrated an increased risk of IHPS

EvidenceUpdates2015

20. Azithromycin (Zedbac®)

Azithromycin (Zedbac®) Azithromycin (Zedbac®) Azithromycin (Zedbac®) All Wales Medicines Strategy Group (AWMSG) Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). Azithromycin (Zedbac®) Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG (...) Secretariat Assessment Report Advice No. 1914. 2014 Authors' conclusions Azithromycin (Zedbac®) 500 mg powder for solution for infusion is recommended as an option for restricted use within NHS Wales. Azithromycin (Zedbac®) 500 mg powder for solution for infusion should be restricted for use within NHS Wales for the treatment of community-acquired pneumonia (CAP) due to susceptible microorganisms, in adult patients where initial intravenous therapy is required. Azithromycin (Zedbac®) 500 mg powder

Health Technology Assessment (HTA) Database.2015